Cary Hsu, M.D.
Cary Hsu, M.D.
Assistant Professor of Surgery
- Assistant Professor of Surgery
Michael E. DeBakey Department of Surgery
Division of Surgical Oncology
Baylor College of Medicine
Houston, Texas United States
- Ben Taub Hospital (Hospital)
1504 Taub Loop
Houston, TX 77030
- BS from University of Michigan
- 04/1995 - Ann Arbor, Michigan United States
- Cellular and Molecular Biology
- MS from Temple University School of Medicine
- 05/2001 - Philadelphia, Pennsylvania United States
- Residency at UCLA Medical Center
- 06/2008 - Los Angeles, California United States
- Clinical Fellowship at Surgery Branch of the National Cancer Institute
- 06/2006 - Bethesda, Maryland United States
- Fellowship at The University of Texas MD Anderson Cancer Center
- 06/2011 - Houston, United States
- #054486, 10/2009
- American Board of Surgery
- Surgical Oncology
Professional StatementCary Hsu, M.D., assistant professor of Surgery, is a surgical oncologist at Ben Taub Hospital and committed to caring for underserved patients in Houston.
Dr. Hsu earned a degree in Cellular and Molecular Biology at the University of Michigan and completed medical school at Temple University School of Medicine. He completed his residency at UCLA and a clinical fellowship at the National Cancer Institute. Dr. Hsu received fellowship training in surgical oncology at MD Anderson Cancer Center.
Dr. Hsu's clinical interest is in the multidisciplinary management of solid tumors. The multidisciplinary team at Ben Taub is committed to providing evidence-based, state of the art care for all cancer patients. Dr. Hsu is also engaged in the training of students and residents at the Baylor College of Medicine. Dr. Hsu's research interests include clinical outcomes in surgical oncology and cancer immunotherapy.
- 1. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du BN "Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R." : Pubmed PMID: 9763535
- 2. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke SS, and La Du BN "Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase." : Pubmed PMID: 10421458
- 3. Doorn JA, Sorenson RC, Billecke SS, Hsu C, and La Du BN "Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase." : Pubmed PMID: 10421457
- 4. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, and La Du BN "Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity." : Pubmed PMID: 10479665
- 5. Hsu C, Kershaw MH, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, and Hwu P "Immunization against endogenous retroviral tumor-associated antigens." : Pubmed PMID: 11691813
- 6. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA "Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine." : Pubmed PMID: 16301627
- 7. Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J, Robbins PF, Peng PD, Shen X, Gomes TJ, Dunbar CE, Munroe DJ, Stewart C, Cornetta K, Wangsa D, Ried T, Rosenberg SA, and Morgan RA "Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene." : Pubmed PMID: 17353346
- 8. Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma, A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo, NP, and Morgan RA "T-cell receptor gene therapy of established tumors in a murine melanoma model." : Pubmed PMID: 18157006
- 9. Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, Zhao Y, Abad J, Zheng Z, Rosenberg SA, and Morgan RA "Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes." : Pubmed PMID: 19265475
- 10. Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y, Zheng, Z, Rosenberg SA, and Morgan RA "Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity." : Pubmed PMID: 19494842
Log In to edit your profile